Medmix

Medmix, headquartered in CH and operating within the "Other business services (74)" sector, has established significant climate commitments and has begun reporting on its carbon emissions.

For the fiscal year 2025, Medmix reported Scope 1 emissions of approximately 4,127,000 kg CO2e and Scope 2 emissions of approximately 5,049,000 kg CO2e. In 2024, the company's Scope 1 emissions were approximately 4,145,000 kg CO2e, with Scope 2 emissions at approximately 5,848,000 kg CO2e. In 2023, Medmix recorded Scope 1 emissions of approximately 4,432,000 kg CO2e and Scope 2 emissions of approximately 5,525,000 kg CO2e. The most comprehensive emissions data is available for 2022, which includes Scope 1 emissions of approximately 5,408,000 kg CO2e, Scope 2 emissions of approximately 1,545,000 kg CO2e, and Scope 3 emissions totalling approximately 67,803,000 kg CO2e.

Medmix has set ambitious targets to reduce its environmental impact. The company aims for a 50% reduction in absolute carbon footprint emissions by 2030, using 2019 as a baseline year. Furthermore, Medmix has committed to ambitious Science Based Targets (SBTi) for emissions reductions. This includes a near-term target to reduce absolute Scope 1 and 2 GHG emissions by 80% by 2029 from a 2019 base year. Concurrently, Medmix aims to reduce absolute Scope 3 GHG emissions by 42% by 2029. The company's long-term vision aligns with net-zero, with a commitment to reduce absolute Scope 1, 2, and 3 GHG emissions by 90% by 2050 from the 2019 baseline. Medmix also commits to reaching net-zero greenhouse gas emissions across its value chain by 2050. The company's SBTi targets are classified as 1.5°C aligned.